Previous Close | 189.93 |
Open | 191.94 |
Bid | 118.25 x 800 |
Ask | 309.85 x 900 |
Day's Range | 190.80 - 194.50 |
52 Week Range | 110.45 - 211.13 |
Volume | |
Avg. Volume | 551,713 |
Market Cap | 10.834B |
Beta (5Y Monthly) | 1.03 |
PE Ratio (TTM) | 262.50 |
EPS (TTM) | 0.74 |
Earnings Date | Apr 30, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 204.53 |
Subscribe to Yahoo Finance Plus to view Fair Value for RGEN
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This appointment expands the size of Repligen’s board from eight to nine members. Ms. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies. This includes eight years with Thermo Fisher Scientific, where, from 2016–2020, she ser
It is hard to get excited after looking at Repligen's (NASDAQ:RGEN) recent performance, when its stock has declined...
Repligen Corp (NASDAQ:RGEN), a bioprocessing company focused on the development, manufacture, and commercialization of products used in the process of drug manufacturing, has reported an insider sale according to a recent SEC filing.